ZNTL · Zentalis Pharmaceuticals, Inc.
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| — | $0 | $67.43M | $0 | $0 | — | — | — | |
| $116.32M | $107.3M | $167.77M | $189.59M | $172.73M | $175.6M | $84.9M | $38.39M | |
| $37.06M | $37.72M | $87.12M | $64.35M | $54.55M | $40.94M | $33.89M | $8.46M | |
| $620K | $739K | $1.29M | $1.39M | $1.43M | $544K | $160K | $111K | |
| $0 | $7.8M | $0 | $0 | — | — | — | — | |
| $153.37M | $152.81M | $258.62M | $299.51M | $227.29M | $216.54M | $118.79M | $46.85M | |
| -$153.37M | -$152.81M | -$191.19M | -$299.51M | -$227.29M | -$216.54M | -$118.79M | -$46.85M | |
| — | — | -283.57% | — | — | — | — | — | |
| -$152.75M | -$152.07M | -$189.91M | -$298.12M | -$225.86M | -$216M | -$118.63M | -$46.73M | |
| — | $0 | $0 | -$16.01M | -$16.28M | -$1.83M | $0 | $0 | |
| -$138.85M | -$136.62M | -$165.69M | -$292.91M | -$237.58M | -$166.39M | -$118.1M | -$46.36M | |
| $700K | $442K | $177K | -$601K | -$469K | -$297K | $444K | $15K | |
| -$139.55M | -$137.06M | -$165.84M | -$292.19M | -$236.81M | -$158.73M | -$117.84M | -$45.66M | |
| — | — | -245.96% | — | — | — | — | — | |
| — | $0 | -$28K | -$114K | -$307K | -$7.37M | -$707K | -$715K | |
| -$139.68M | -$137.42M | -$167.48M | -$288.64M | -$238.03M | -$158.89M | -$117.81M | -$45.66M | |
| USD/shares | -$1.96 | -$1.91 | -$2.33 | -$4.47 | -$4.48 | -$3.72 | -$4.19 | — |
| USD/shares | -$1.96 | -$1.91 | -$2.33 | -$4.47 | -$4.48 | -$3.72 | -$4.19 | -$8.16 |
| shares | — | 71.87M | 71.08M | 65.41M | 52.86M | 42.69M | 28.11M | 5.6M |
| shares | — | 71.87M | 71.08M | 65.41M | 52.86M | 42.69M | 28.11M | 5.6M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2025: $9.98M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 314 similar-size Biotechnology companies (of 516 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $0 | $67,425,000 | $0 | $0 |